Juniper Biosciences Announces Strategic Collaboration with leading global cancer center on F-MISO (JBS-003)
Juniper Biosciences today announced a strategic licensing agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the development of JBS-003 (18F-fluoromisonidazole, or FMISO)...
Read more
Upsized and Oversubscribed Seed Round Completed at $40 Million
Juniper Biosciences LLC today announced the closing of an oversubscribed and upsized $40 million seed financing through its parent company, Juniper Radiopharma LLC, co-led by NovaCapital, several high-net-worth individuals, and members of the Club Degli Investitori.
Read more